Skip to main content
SpringerLink
Log in

Breast Cancer Chemoprevention

  • Chapter
  • First Online:
Breast Cancer Risk Reduction and Early Detection

Abstract

A significant amount of evidence has accumulated from randomized clinical trials supporting the use of pharmacologic agents for breast cancer risk reduction. All of these trials have capitalized on the known expression of estrogen receptors on many breast cancer cells, and the demonstrated efficacy of selective estrogen receptor modulators (SERMs) to treat breast cancer. Two SERMs, tamoxifen and raloxifene, have been studied extensively in randomized, controlled trials, and both have been shown to reduce the risk of invasive ER-positive breast cancer by approximately 50% in women at increased risk. Other benefits that have been documented are a decrease in fractures for both drugs, and a decrease in noninvasive breast cancer and benign breast disease for tamoxifen. The risk of venous thromboembolic events and vasomotor symptoms is increased for both drugs. In addition, tamoxifen is associated with a twofold increase in endometrial cancer, and a modest increase in cataracts and cataract surgery. Studies are underway to explore the role of aromatase inhibitors for breast cancer risk reduction. In addition, several novel pharmacologic and natural compounds are being considered for future trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jordan VC, Knudson AG. Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology (Williston Park). May 2006;20(6):553–562:discussion 567–558, 573, 577.

    Google Scholar 

  2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. Nov 16, 2005;97(22):1652–1662.

    Article  CAS  PubMed  Google Scholar 

  3. Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. Dec 20, 2007;25(36):5815–5824.

    Article  CAS  PubMed  Google Scholar 

  4. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. Feb 21, 2007;99(4):283–290.

    Article  CAS  PubMed  Google Scholar 

  5. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. Dec 20, 1989;81(24):1879–1886.

    Article  CAS  PubMed  Google Scholar 

  6. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. Nov 3, 1999;91(21):1829–1846.

    Article  CAS  PubMed  Google Scholar 

  7. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. Sep 16, 1998;90(18):1371–1388.

    Article  CAS  PubMed  Google Scholar 

  8. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. Sep 1999;17(9):2659–2669.

    CAS  PubMed  Google Scholar 

  9. Tan-Chiu E, Wang J, Costantino JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst. Feb 19, 2003;95(4):302–307.

    Article  CAS  PubMed  Google Scholar 

  10. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. Feb 21, 2007;99(4):272–282.

    Article  CAS  PubMed  Google Scholar 

  11. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. Oct 1, 2003;21(19):3588–3593.

    Article  CAS  PubMed  Google Scholar 

  12. Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. Aug 20, 2006;24(24):3991–3996.

    Article  CAS  PubMed  Google Scholar 

  13. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. Jan 15, 2003;95(2):160–165.

    Article  CAS  PubMed  Google Scholar 

  14. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. May 2, 2007;99(9):727–737.

    Article  CAS  PubMed  Google Scholar 

  15. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. Feb 8, 2005;111(5):650–656.

    Article  CAS  PubMed  Google Scholar 

  16. Fallowfield L, Fleissig A, Edwards R, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol. Apr 1, 2001;19(7):1885–1892.

    CAS  PubMed  Google Scholar 

  17. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. Aug 18, 1999;282(7):637–645.

    Article  CAS  PubMed  Google Scholar 

  18. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. Jun 16, 1999;281(23):2189–2197.

    Article  CAS  PubMed  Google Scholar 

  19. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. Feb 20, 2002;287(7):847–857.

    Article  CAS  PubMed  Google Scholar 

  20. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. Dec 1, 2004;96(23):1751–1761.

    Article  CAS  PubMed  Google Scholar 

  21. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res. Sep 1, 2006;12(17):5242–5247.

    Article  CAS  PubMed  Google Scholar 

  22. Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol. Dec 1, 2002;90(11):1204–1210.

    Article  CAS  PubMed  Google Scholar 

  23. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. Jul 13, 2006;355(2):125–137.

    Article  CAS  PubMed  Google Scholar 

  24. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. Jun 21, 2006;295(23):2727–2741.

    Article  CAS  PubMed  Google Scholar 

  25. Vogel VG. Chemoprevention strategies 2006. Curr Treat Options Oncol. Feb 2007;8(1):74–88.

    Article  PubMed  Google Scholar 

  26. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. Jun 21, 2006;295(23):2742–2751.

    Article  CAS  PubMed  Google Scholar 

  27. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. Nov 2003;18(11):937–947.

    Article  PubMed  Google Scholar 

  28. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. Jan 25, 2003;361(9354):296–300.

    Article  CAS  PubMed  Google Scholar 

  29. U.S. Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. Jul 2, 2002;137(1):56–58.

    Google Scholar 

  30. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol. Mar 10, 2005;23(8):1644–1655.

    Article  CAS  PubMed  Google Scholar 

  31. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. Jama. Nov 14, 2001;286(18):2251–2256.

    Article  CAS  PubMed  Google Scholar 

  32. Lippman SM, Brown PH. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst. Nov 3, 1999;91(21):1809–1819.

    Article  CAS  PubMed  Google Scholar 

  33. Williams KP, Resche DH, Livingston JN. Recruiting African American women into chemoprevetnion trials: Gail model as an education tool. International Journal of Cancer Prevention. 2004;1(1):63–68.

    Google Scholar 

  34. Nguyen TT, Somkin CP, Ma Y. Participation of Asian-American women in cancer chemoprevention research: physician perspectives. Cancer. Dec 15, 2005;104(12 Suppl):3006–3014.

    Article  PubMed  Google Scholar 

  35. Recommendations of the clinical trials consensus panel. National Medical Association. J Natl Med Assoc. Oct 2000;92(10):464–471.

    Google Scholar 

  36. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. Apr 2, 2003;95(7):526–532.

    Article  CAS  PubMed  Google Scholar 

  37. Lippman SM. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol. Oct 2006;3(10):523.

    Article  PubMed  Google Scholar 

  38. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer. Sep 2006;13(3):827–837.

    Article  CAS  PubMed  Google Scholar 

  39. Geller BA, Vogel VG. Chemoprevention of breast cancer in postmenopausal women. Breast Dis. 2005;24:79–92.

    CAS  PubMed  Google Scholar 

  40. Castrellon AB, Gluck S. Chemoprevention of breast cancer. Expert Rev Anticancer Ther. Mar 2008;8(3):443–452.

    Article  CAS  PubMed  Google Scholar 

  41. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem. 2007;42:193–212.

    Article  PubMed  Google Scholar 

  42. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. Feb 2006;6(2):130–140.

    Article  CAS  PubMed  Google Scholar 

  43. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. Jun 2007;7(6):599–608.

    Article  CAS  PubMed  Google Scholar 

  44. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. Sep 15 2003;63(18):6096–6101.

    CAS  PubMed  Google Scholar 

  45. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer. Feb 13, 2006;94(3):346–350.

    Article  CAS  PubMed  Google Scholar 

  46. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. Mar 2006;13(1):51–68.

    Article  CAS  PubMed  Google Scholar 

  47. Bonanni B, Lazzeroni M, Veronesi U. Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther. Apr 2007;7(4):423–432.

    Article  CAS  PubMed  Google Scholar 

  48. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. May 28, 2007;167(10):1050–1059.

    Article  CAS  PubMed  Google Scholar 

  49. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus Vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. Nov 19, 2008;100(22):1581–1591.

    Article  CAS  PubMed  Google Scholar 

  50. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin. Jan 2008;24(1):139–149.

    CAS  PubMed  Google Scholar 

  51. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. Mar 2008;10(3):475–510.

    Article  CAS  PubMed  Google Scholar 

  52. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. May 2007;64(9):1105–1127.

    Article  CAS  PubMed  Google Scholar 

  53. Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem. Apr 2006;6(4):401–407.

    Article  CAS  PubMed  Google Scholar 

  54. Lanzilli G, Fuggetta MP, Tricarico M, et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol. Mar 2006;28(3):641–648.

    CAS  PubMed  Google Scholar 

  55. Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res. May 2005;49(5):462–471.

    Article  PubMed  CAS  Google Scholar 

  56. Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. Nov 2007;72(13):829–842.

    Article  CAS  PubMed  Google Scholar 

  57. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin Cancer Res. Jun 15, 2006;12(12):3661–3697.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professor and Chair of the Clinical Genetics Department, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA

    Mary B. Daly

Authors
  1. Mary B. Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary B. Daly .

Editor information

Editors and Affiliations

  1. School of Medicine & Health Sciences, University of North Dakota, N. Columbia Road 501, Grand Forks, 58203, U.S.A.

    Edward R. Sauter

  2. Dept. Medical Oncology, Fox Chase Cancer Center, Cottman Ave. 333, Philadelphia, 19111-2497, U.S.A.

    Mary B. Daly

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Daly, M.B. (2010). Breast Cancer Chemoprevention. In: Sauter, E., Daly, M. (eds) Breast Cancer Risk Reduction and Early Detection. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-87583-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-87583-5_3

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-87582-8

  • Online ISBN: 978-0-387-87583-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation